Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share were down 92.50% year over year to $0.03, which missed the estimate of $0.04.

Revenue of $342,406,000 declined by 3.79% year over year, which beat the estimate of $330,730,000.

Outlook

Horizon Therapeutics raised FY21 net sales guidance from $2.7 billion-$2.8 billion to $2.75 billion-$2.85 billion.

Conference Call Details

Date: May 05, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/jkv3iws7

Technicals

52-week high: $97.20

Company's 52-week low was at $35.04

Price action over last quarter: Up 0.18%

Company Overview